Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

CKD-828 Primary Hypertension Trial(Dose-selection)

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: S-Amlodipine, Telmisartan
Drug: S-Amlodipine
Drug: Telmisartan

First Posted Date: 2010-05-21

Last Posted Date: 2011-04-26

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 430

Registration Number: NCT01128322

Locations: 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
🇰🇷
DonGuk University International Hospital, Goyang, Korea, Republic of

and more 23 locations

Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-501 0.5mg
Drug: Pioglitazone 15mg

First Posted Date: 2010-04-19

Last Posted Date: 2013-02-15

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 253

Registration Number: NCT01106131

Locations: 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of

The Effect of Food on the Pharmacokinetic Characteristics of CKD-501

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CKD-501 1mg

First Posted Date: 2010-02-19

Last Posted Date: 2010-12-10

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01071720

Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: CKD-501 0.5mg
Drug: Placebo
Drug: CKD-501 2mg
Drug: CKD-501 1mg

First Posted Date: 2009-12-11

Last Posted Date: 2009-12-16

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 214

Registration Number: NCT01030679

Locations: 🇰🇷
The Yeungnam University Hospital, Daegu, Korea, Republic of
🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷
The Inje University Medical Center, Busan, Korea, Republic of

and more 5 locations

Dyslipidemia in Cardiovascular Disease

Phase 4

Completed

Conditions: Dyslipidemia

Interventions: Drug: Atorvastatin (Lipilou)
Drug: Atorvastatin (Lipitor)

First Posted Date: 2009-12-10

Last Posted Date: 2012-08-09

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 244

Registration Number: NCT01029522

Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: CKD-516 inj

First Posted Date: 2009-12-09

Last Posted Date: 2011-12-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT01028859

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Belotecan

First Posted Date: 2009-12-01

Last Posted Date: 2016-01-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 52

Registration Number: NCT01022671

Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer

Phase 1

Completed

Conditions: Advanced Solid Cancers

Interventions: Drug: CKD-810, Taxotere inj.

First Posted Date: 2009-11-25

Last Posted Date: 2010-12-16

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 44

Registration Number: NCT01019941

Locations: 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of
🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷
Gachon University Gil Hospital, Inchon, Korea, Republic of

and more 4 locations

Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 (Mycophenolate Mofetil) Tablet

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CKD-4101 tablet
Drug: Mycophenolate Mofetil capsule

First Posted Date: 2009-11-19

Last Posted Date: 2009-11-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 28

Registration Number: NCT01016626

Locations: 🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of

Drug Interaction Between CKD-501 and Metformin

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: Metformin
Drug: CKD-501

First Posted Date: 2009-10-30

Last Posted Date: 2011-01-12

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01005160

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy